Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144759 | 1.00 | PDPK1 (0.41) | PDPK1KLKB1EHMT2MASP2NAMPT | |
| SCHEMBL3144731 | 1.00 | PDPK1 (0.41) | PDPK1KLKB1EHMT2MASP2NAMPT | |
| SCHEMBL1432560 | 0.99 | EHMT2 (0.41) | PDPK1KLKB1EHMT2MASP2NAMPT | |
| SCHEMBL1432137 | 0.89 | EHMT2 (0.44) | KLKB1EHMT2MASP2NAMPTFURIN | |
| SCHEMBL1431920 | 0.89 | EHMT2 (0.47) | KLKB1EHMT2MASP2NAMPTFURIN | |
| SCHEMBL1432213 | 0.89 | EHMT2 (0.47) | KLKB1EHMT2MASP2NAMPTFURIN | |
| SCHEMBL3139985 | 0.89 | EHMT2 (0.47) | KLKB1EHMT2MASP2NAMPTFURIN | |
| SCHEMBL1432414 | 0.87 | CTSL (0.44) | KLKB1 | |
| SCHEMBL3148190 | 0.87 | HRH3 (0.41) | KLKB1EHMT2MASP2NAMPTFURIN | |
| SCHEMBL3148342 | 0.87 | HRH3 (0.41) | KLKB1EHMT2MASP2NAMPTFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | PDPK1 1972/4885KLKB1 3491/4885EHMT2 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.